anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ketarolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction.

One drop (0.05 mL) of 0.5% ketorolac tromethamine ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 normal subjects. Only 5 of 26 subjects had a detectable amount of ketorolac in their plasma (range 10.7 to 22.5 ng/mL) at Day 10 during topical ocular treatment. When ketorolac tromethamine 10 mg is administered systemically every 6 hours, peak plasma levels at steady state are around 960 ng/mL.

In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ketorolac tromethamine ophthalmic solution 0.4% or its vehicle QID for up to 4 days. Significant differences favored ketorolac tromethamine ophthalmic solution for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.

Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure.

The safety and effectivess of ketorolac tromethamine ophthalmic solution in post-cataract surgery patients has not been established.
A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. This syndrome includes alterations in mood, sleep disturbances, and cognitive performance. Many of nicotine's withdrawal symptoms are similar to those observed with marijuana withdrawal. Bupropion has been shown to be effective in treating nicotine addiction.The purpose of this study is to determine if bupropion is effective in treating marijuana dependent individuals. Specifically, this study will determine if bupropion alleviates withdrawal symptoms associated with marijuana abuse.

Participants in this 21-day, double-blind study will be randomly assigned to receive either bupropion or placebo. Treatment with bupropion will occur for one week before stopping marijuana use (quit day). Bupropion will be administered at 150 mg per day for 3 days, followed by 300 mg per day for the remainder of the study. Quit day will occur on Day 8, at which time participants will be required to remain abstinent from marijuana for the duration of the study. Participants will provide daily urine specimens. Changes in vigilance, memory, reaction time, and psychomotor performance as well as withdrawal symptoms will be evaluated.
INTRODUCTION: cervical cancer is a health concern worldwide. The South Kivu Province in the Eastern DR Congo is facing many cases of this disease but poorly screened and reported. The objective of this was to determine the prevalence of cell abnormalities at cervical cytology in a tertiary teaching hospital in Bukavu and their association with common risk factors of cervical cancer.
METHODS: a cross-sectional study was conducted on 142 women attending the Provincial Referral Hospital of Bukavu (HPGRB) from February to December 2021. Quantitative variables were described by their median following their asymmetric distributions and the qualitative variables in absolute and relative frequencies. Then the Chi-square test was used for the comparison of proportion.
RESULTS: forty-five percent of the participants had between three and five children. Twenty-two (15.5%) of the 142 patients reported to have two or more sexual partners and 17.5% reported the use of hormonal contraception. The prevalence of cell abnormalities at cervical cytology was 17% of which Low- Grade Squamous Intraepithelial Lesion (LSIL) was the most representative (12.9%). There was no statistically significant association between the common cervical risk factors and the occurrence of cell abnormalities.
CONCLUSION: cervical pre-cancerous lesions are frequent in South Kivu province. The Pap smear test remains an early and affordable screening method and constitutes a secondary prevention strategy in women of 18 years and older in a low-income country such as DR Congo where vaccination against HPV is still hypothetic.
BACKGROUND AND OBJECTIVE: Corticosteroids are commonly used for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF); however, the optimal initial dose of corticosteroids remains uncertain due to a lack of sufficient evidence. We evaluated whether the administration of a pulse dose of corticosteroids resulted in improved survival outcomes compared with conventional non-pulse dose of corticosteroids.
METHODS: We retrospectively analysed 238 patients with AE-IPF treated with corticosteroids at a tertiary referral hospital between January 2013 and December 2021. Based on whether a pulse dose of corticosteroids (methylprednisolone of ≥250 mg/day or equivalent) was administered within 7 days of hospitalization for AE-IPF, the patients were divided into the pulse and non-pulse regimen groups. The survival outcomes were compared between the two groups using multivariable regression and propensity score-matched analyses.
RESULTS: Among the 238 patients, 59 patients received pulse dose of corticosteroids, whereas 179 patients received conventional non-pulse dose of corticosteroids. After adjusting for the confounding factors related to the baseline clinical and radiographic severity, compared with the conventional non-pulse regimen, the pulse regimen of corticosteroids did not reduce the risk of mortality at the 3-month (aHR 0.84, 95% CI 0.45-1.38) or 12-month (aHR 0.96, 95% CI 0.60-1.25) follow-ups. Propensity score-matched analysis revealed similar results.
CONCLUSION: The survival outcomes of patients with AE-IPF who received a pulse dose of corticosteroids did not differ from those of patients who received conventional non-pulse dose of corticosteroids. Further prospective studies are required to establish the optimal initial dose of corticosteroids for the treatment of AE-IPF.
Physiologically synergistic mixtures of pomegranate extracts and methods of use thereof. Physiologically synergistic mixtures of pomegranate extracts are provided. A first mixture includes a pomegranate juice extract; and pomegranate seed oil. A second mixture includes pomegranate pericarp extract; and pomegranate seed oil. A third mixture a pomegranate pericarp extract; and a pomegranate juice extract. Disclosed methods inclod preparing components of disclosed mixtures, preparing the mixtures from the components and administering the resultant mixture to a subject in a physiologically effective amount so that a progression of a cell proliferation disorder is retarded.
In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
A consolidation engine to consolidate health information under regulatory control and from healthcare entities and patients is described. Data sources corresponding to healthcare providers and/or healthcare payers are accessed. A first set of confidential medical information from a first data source for an identified patient is accessed, including a first indication of a health condition and/or a first indication of a health care service. A second set of confidential medical information from a second data source is accessed, including a second indication of a health condition and/or a second indication of a health care service. First and second sets are consolidated to form a composite set of confidential medical information. Authentication information for a user approved for access to at least part of the composite set is stored, and a network interface allows access by the user that is approved for access to the composite set of confidential medical information.
Roux-en-y gastric bypass (RYGB) surgery leads to improvements in diabetes that occurs even before any significant weight loss is seen. What are the reasons for this? There is evidence in animals that changes in the composition of gut bacteria after RYGB may be responsible for improvements in how glucose is metabolized in the body. The study aims to correlate changes in the bacterial composition of the gut that occurs after surgery with improvements in glucose metabolism in people with type 2 diabetes. The investigators will do this by using validated methods to measure glucose metabolism and cutting edge technology to analyze the gut microbiome. A parallel group of patients with similar weight, height and age will undergo caloric restriction alone to mimic weight loss seen after RYGB. Participants will also undergo similar glucose metabolism studies and analysis of their gut bacterial composition. Thus, any difference seen between groups can be attributed to the surgery itself and may lead to identification of novel therapeutic options for diabetes.
The secrecy surrounding HIV continues to be a major concern for older people living with HIV (OPWH) despite their long-term experience of HIV and the presence of other chronic diseases. Our study aims to highlight how the secrecy surrounding HIV can affect the management of the other conditions. The results of this socio-anthropological sub-study of the ANRS EP66 SEPTAVIH study, which assesses frailty in OPWH, are based on in-depth interviews conducted with 20 OPWH with multimorbidities aged 70 years and over and 9 caregivers. Based on a cross-sectional thematic analysis, this study shows that HIV infection differs from other chronic diseases due to the secrecy and stigma associated with HIV. These specific issues associated with HIV complicate the lives of OPWH, depriving them of support from loved ones and forcing them to exclude their general practitioner from their care system. This then causes OPWH with multiple chronic diseases to become socially vulnerable and isolated. Interventions that support the sharing of information on HIV among OPWH and also among caregivers need to be identified as a matter of urgency in order to improve the lives and management of OPWH with multimorbidities.Trial Registration: ClinicalTrials.gov identifier: NCT03958786.
In intervention group I - clamped at a distance of 2 cm - umbilical cord was measured 2 cm from the abdominal wall in the delivery room and clamped. This procedure was carried out by a single researcher using a 2 cm standard measuring tool (cut-to-size ruler) prepared before hand. In order to ensure standardization, this tool was cleaned with a disinfectant and used to measure the umbilical clamp distance of all newborns in the intervention group I.
Participants will complete app-based cognitive-behavioral therapy (CBT) treatment for major depressive disorder (MDD) through their personal mobile smartphone. They will also be assigned a therapist, who will provide brief virtual treatment sessions (up to 25 minutes via a video platform) over the course of the same treatment period.
Participants that have a chronic preventable disease and food insecurity will be offered enrollment in the study. Once all participants are enrolled, they will be given weekly boxes of food which includes materials for a nutritious recipe and extra fruit and vegetables for a total of 6 weeks. The SNAP-Ed Educator and SHIP Public health coordinator will be present at food pick up to answer questions about the boxes, food preparation, etc. They will be given the option of participating in grocery store and farmer's market tours, as well as sign up for text messaging of nutrition information and recipes. At the end of 6 weeks, they will be asked to participate in a focus group. At baseline, 3 months and 6 months, they will be asked to complete a survey on lifestyle behaviors and food choices.
The invention discloses a medicine-and-food dual-purpose preparation for treating pneumoconiosis, clearing away the lung-heat and nourishing the heart and a preparation method for the medicine-and-food dual-purpose preparation. The medicine-and-food dual-purpose preparation is made of aizoon stonecrop herb, herba houttuyniae, polygonatum kingianum, polygonatum odoratum, platycodon grandiflorum, almond, radix glycyrrhizae, lilies, folium mori, white fungus, coix seed, citrus, mint and green tea. The medicine-and-food dual-purpose preparation can be used as a medicine and has the functions of clearing away the lung-heat, relieving cough and reducing sputum and the functions of promoting blood circulation to remove blood stasis, nourishing the heart and smoothing the sphygmus. The medicine-and-food dual-purpose preparation is also healthy food. The raw materials adopted by the medicine-and-food dual-purpose preparation are medicine-and-food medicines, can be eaten for a long time and cannot generate any toxic and side effect on a human body. The medicine-and-food dual-purpose preparation is healthy and health-protection; the lung organ is stimulated to secrete mucus and promote sputum excretion through functions of the components, and the self-cleaning function of the lung is realized; the blood is purified; the oxyhemoglobin saturation is enhanced; the heart can be protected from being injured; therefore, the medicine-and-food dual-purpose preparation has the effects of preventing and treating the pneumoconiosis and cardiovascular diseases.
Patients undergoing the cavernous tissue sparing penile implant procedure will be injected intraoperatively with 40µg alprostadil, a prostaglandin E1 agonist intracorporal injection (ICI). The procedure will begin as soon as maximal tumescence is attained.

In the cavernous sparing group, corporal dilation will be done solely with a size 8 dilator. The insertion of the dilator will be carefully inserted in what we call the path of least resistance. To determine the path of least resistance, the corporotomy is spread apart by pulling on previously set stay sutures. The path of least resistance is the plane with maximum outflow of blood from the intraoperatively pharmaceutically dilated and blood filled corpora cavernosa. This plane can also be anticipated with a preoperative penile duplex.
The disclosed is a kind of multiple modified derivatives of gelatin having not only the structure of formula (I) but also one of structures of formula (II), (III), and (IV) as well. Wherein, G refers to gelatin residue comprising type A, type B and the type of gene recombination; R 1  refers to allylene, or a linkage group with amide; R 2  refers to alkyl, or aryl; R 3  refers to alkylene; R 4  refers to carboxyl or carboxylate. The multiple modifying ways of gelatin comprise the hydrophobic modification on the amino group of gelatin through amide bond, carboxylation on the amino group of gelatin through amide bond, thiolation on the carboxyl group of gelatin, and thiolation following carboxylation on amino group of gelatin through amide bond. In addition, the invention also discloses the crosslinked material made of multiple modified derivatives of gelatin. The multiple modified derivatives of gelatin have flexible chemical structures and many properties. Their crosslinked gelatin material can be used the matrix for cell growth etc.
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious 5 viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides for the use of these modified viral particles in the preparation of medicaments for prevention and/or treatment of one 10 or more viral diseases in a patient. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine 15 composition of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.
The invention relates to an application of a Chinese asafoetida seed extract to preparation of an antitumor medicament. The invention relates to a fat-soluble extract of Chinese asafoetida seeds and an application of the fat-soluble extract to product with an anti-tumor function. Chinese asafoetida seeds are extracted by using a steam distillation method, a supercritical technology or a fat-soluble solvent, and are analyzed by using a gas chromatography-mass spectrometry technology. The Chinese asafoetida seed extract has strong restraining effects on colon cancer, cervical cancer and hepatoma cells. The anti-tumor medicament provided by the invention can be an injection, a capsule, a tablet, a particle or in other dosage forms. The asafoetida seeds can be seeds of ferula sinkiangensis, fukangensis or ferula ovina. An anti-tumor preparation prepared from the Chinese asafoetida seed extract is mainly applied to treatment of tumor patients.
Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
In a cardiac monitoring method, at east an inactive natriuretic peptide ( 22 ) and an active natriuretic peptide ( 20 ) are assayed in a biological sample taken from a patient. Both the inactive and active natriuretic peptides are produced in the patient responsive to cardiac stress. A therapeutic agent ( 26 ), such as a synthetic or mimetic natriuretic peptide, is administered to the patient. The administered therapeutic agent substantially interferes with the active natriuretic peptide assay but does not substantially interfere with the inactive natriuretic peptide assay. Kinetics of the administered therapeutic agent are determined based on at least the active natriuretic peptide assay. Cardiac diagnostic information is determined based on at least the inactive natriuretic peptide assay.
Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
Patients receive retifanlimab IV over 30-60 minutes on day 1 and telotristat ethyl PO TID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
OBJECTIVES: This study aimed to perform a "proof of concept" pilot and assess patient satisfaction of pharmacist provision of medication abortion utilizing an implementation toolkit.
STUDY DESIGN: Pharmacists completed an online and in-person training followed by an online assessment prior to participating in the pilot. Pharmacists provided medication abortion care using a "no-test" protocol and an implementation toolkit. Participants were administered 200 mg of mifepristone orally on the day of their abortion visit and instructed to take 800 mcg of misoprostol buccally 24 to 48 hours later (with an additional 800 mcg buccally 4 hours after the first dose for patients 63-70 days' gestation). Visits were completed in person in a private room adjacent to the pharmacy. We assessed the rate of completed abortions and any complications. Following their abortion, patients completed a brief interviewer-administered survey and semistructured qualitative interview.
RESULTS: Ten patients completed medication abortion visits. Nine of 10 participants had complete abortions. One participant identified that she did not pass her pregnancy and underwent an in-office aspiration. One participant visited an emergency department for pain and received pain medication. No serious adverse events occurred. All patients completed the postabortion survey, and all were "very satisfied" with their abortion experience. Nine patients completed postabortion interviews.
CONCLUSIONS: In this pilot study, pharmacists were successful at providing medication abortion to patients. Satisfaction was high, and complications were uncommon.
IMPLICATIONS: Patients were highly satisfied with pharmacist provision of medication abortion and are likely to utilize this service if available.
Disclosed are a protein (TP) and proteins which are related thereto. Said proteins are involved in the development of the nervous system, especially the central nervous system, and are expressed in a tissue-specific and development-specific manner. The invention also relates to DNA sequences that code said proteins and antibodies or fragments thereof which are directed against said proteins. The invention further relates to antisense RNA or ribozymes which are directed against the expression of the proteins. Disclosed are medicaments and diagnostic processes in which the above-mentioned compounds are used. The invention further relates to a non-human mammal whose TP-coding gene is modified.